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Background: Chronic obstructive pulmonary disease (COPD) is considered to be a   respiratory 
disease with systemic manifestations. Some multidimensional staging systems, not based solely 
on the level of airflow limitation, have been developed; however, these systems have rarely 
been compared.
Methods: We previously recruited 150 male outpatients with COPD for an analysis of factors 
related to mortality. For this report, we examined the discriminative and prognostic predictive 
properties of three COPD multidimensional measurements. These indices were the modified 
BODE (mBODE), which includes body mass index, airflow obstruction, dyspnea, and exer-
cise capacity; the ADO, composed of age, dyspnea, and airflow obstruction; and the modified 
DOSE (mDOSE), comprising dyspnea, airflow obstruction, smoking status, and exacerbation 
frequency.
Results: Among these indices, the frequency distribution of the mBODE index was the most 
widely and normally distributed. Univariate Cox proportional hazards analyses revealed that the 
scores on three indices were significantly predictive of 5-year mortality of COPD (P , 0.001). 
The scores on the mBODE and ADO indices were more significantly predictive of mortality 
than forced expiratory volume in 1 second, the Medical Research Council dyspnea score, 
and the St. George’s Respiratory Questionnaire total score. However, peak oxygen uptake on 
progressive cycle ergometry was more significantly related to mortality than the scores on the 
three indices (P , 0.0001).
Conclusion: The multidimensional staging systems using the mBODE, ADO, and mDOSE 
indices were significant predictors of mortality in COPD patients, although exercise capacity 
had a more significant relationship with mortality than those indices. The mBODE index was 
superior to the others for its discriminative property. Further discussion of the definition of 
disease severity is necessary to promote concrete multidimensional staging systems as a new 
disease severity index in guidelines for the management of COPD.
Keywords: COPD, multidimensional staging systems, BODE index, ADO index, DOSE 
index
Background
Chronic obstructive pulmonary disease (COPD) is now considered as a respiratory 
disease with systemic manifestations.1 COPD first affects the lungs primarily, and 
then structural and functional changes also take place in other organs. The degree 
of airflow limitation as defined by forced expiratory volume in 1 second (FEV1) has 
been used as an index of disease severity, partly because of its significant relationship 
with mortality.2,3 Guidelines indicate that some multidimensional staging systems 
including systemic components in addition to airflow limitation may be used to assess 
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disease severity,1,4 although the definition of disease severity 
remains elusive.
The BODE index, incorporating measurements of 
  nutrition, airflow limitation, dyspnea, and exercise capacity, 
has been established for multidimensional staging.5 It is use-
ful in predicting mortality and hospitalizations and in reflect-
ing disease modification and progression.6 More simplified 
indices such as the ADO index, composed of age, dyspnea, 
and airflow limitation,7 and the DOSE index, composed of 
dyspnea, airflow limitation, smoking status, and exacerba-
tion frequency,8 have been developed recently and have been 
validated. In two European cohorts, both the ADO index 
and the updated BODE index significantly predicted the 
3-year mortality risk after the first hospital admission due 
to an exacerbation of moderate-to-severe COPD, although 
the original BODE index did not accurately predict such a 
risk.7 The DOSE index was related to a range of clinically 
important outcomes of COPD such as health status, hospi-
tal admission, or respiratory failure, and was predictive of 
exacerbations.8 Although some multidimensional staging 
systems have been developed recently, these indices have 
rarely been compared.
More information about the properties of these indices 
or relationships is needed so that they can be better used 
in clinical practice or trials and, furthermore, be adopted 
concretely in the guidelines in future. We hypothesized that 
the BODE, ADO, and DOSE indices would be useful as 
predictors of mortality in COPD, but that they would have 
some different characteristics. We previously examined the 
factors related to 5-year mortality using multiple measure-
ments in patients with COPD.9 In the present study, by 
reviewing those data, we analyzed the discriminative and 
predictive properties of those multidimensional indices in 
patients with COPD.
Materials and methods
Patients
We previously recruited 150 consecutive male outpatients 
with COPD and analyzed factors related to mortality.9 
Entry criteria included (1) smoking history of more than 20 
pack-years, (2) maximal FEV1/forced vital capacity ratio 
of less than 0.7 and prebronchodilator FEV1 of less than 
80% of the predicted value, (3) regular attendance at Kyoto 
University, Kyoto, Japan, outpatient clinic over 6 months, 
(4) no uncontrolled comorbidities, and (5) no COPD exac-
erbations over the preceding 6 weeks. The study protocol 
was approved by the institutional ethical committee of 
Kyoto University.
Measurements
Pulmonary function tests were performed at least 12 hours 
after the withdrawal of inhaled bronchodilators.9 Patients 
performed spirometry at 15 and 60 minutes after inhaling 
salbutamol (400 µg) and ipratropium bromide (80 µg) using 
a metered-dose inhaler with a spacer device.
Exercise tests were performed on symptom-limited 
  progressive cycle ergometry 60 minutes after the inhalation of 
bronchodilators as described in detail previously.9–11 Patients 
wore a face mask and began unloaded pedaling for 3 minutes, 
after which the workload was increased progressively by an 
increment of 1 W every 3 seconds to the limit of tolerance. 
The exercise data were recorded with an automated exercise 
testing system. Peak oxygen uptake (  Vo2) that was reached 
during exercise was calculated. Predicted values were cal-
culated using the standard equation.12,13
Dyspnea was evaluated by the Japanese version of 
the modified Medical Research Council (MRC) dyspnea 
scale, which is a 5-point scale (0–4) based on degrees of 
various physical activities that precipitate dyspnea.14,15 
Higher scores on the MRC indicate more severe dyspnea. 
Health status was assessed by the Japanese version of the 
St. George’s   Respiratory Questionnaire (SGRQ).9,16,17 The 
SGRQ consists of 50 items divided into the three components 
of symptoms, activity, and impacts, and the total score was 
calculated with scores ranging from 0 to 100. Higher scores 
on the SGRQ indicate a more severe health status.
Multidimensional staging
The BODE index was principally based on the original 
report5 whose score comprises the body mass index (BMI), 
percentage of the predicted FEV1, dyspnea by the MRC, and 
6-minute walking distance (6MWD) as an exercise capacity 
component. Scores ranged from 0 (best status) to 3 (worst 
status) for FEV1 and MRC, and 0 or 1 for BMI. In the present 
study, we employed the modified BODE index (mBODE), 
which used  Vo2 as % predicted, as tested by the progressive 
cycle ergometry instead of the 6MWD, and was previously 
developed and validated.18,19 The % predicted was scored as 
follows: score 0 for .70% predicted, score 1 for 60%–69% 
predicted, score 2 for 40%–59% predicted, and score 3 for 
40,% predicted. Points for each component were added 
together so that the mBODE index ranged from 0 to 10.
The ADO index was calculated based on the original report,7 
with the score comprising age, dyspnea by the MRC, and FEV1. 
Scores ranged from 0 (best status) to 5 (worst status) for age, 
0–3 for MRC, and 0–2 for FEV1. Points for each component 
were added so that the ADO index ranged from 0 to 10.
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The DOSE index was calculated primarily based on the 
original report,8 with scores comprising dyspnea by the MRC, 
FEV1, smoking status, and exacerbation frequency per year. 
Scores ranged from 0 (best status) to 3 (worst status) for 
MRC, 0–2 for FEV1 and the exacerbation frequency, and 0 
or 1 for smoking status. In the present study, the modified 
DOSE (mDOSE) index was calculated using the question 
“During the last year, how many severe or very unpleasant 
attacks of chest trouble have you had?” on the SGRQ, instead 
of exacerbation frequency over the previous year as indicated 
in the original manuscript.8 Points for each component were 
added so that the DOSE index ranged from 0 to 8.
Statistical analysis
Results were expressed as mean ± standard deviation, unless 
otherwise stated. Relationships between the mBODE, ADO, 
and mDOSE indices were analyzed by Spearman’s correla-
tion coefficient tests. The survival status of all patients after 
5 years was assessed. The duration from entry to the last 
attendance or death was recorded. Univariate and multivari-
ate Cox proportional hazards analyses were performed to 
investigate the relationships between the clinical measure-
ments and mortality. Results of regression analyses were 
presented in terms of estimated relative risks (RR) with cor-
responding 95% confidence intervals. P-values of less than 
0.05 were considered to be statistically significant.
Results
Baseline characteristics of the 150 male patients with stable 
COPD are shown in Table 1 and elsewhere.9 Their average 
age was 69 ± 7 years and the postbronchodilator FEV1 was 
47.4% ± 17.4% predicted. The frequency distributions of 
mBODE, ADO, and mDOSE scores are shown in Figure 1. 
The histograms showed widely and virtually normal distribu-
tion of the mBODE scores. The ADO scores were more nar-
rowly distributed than the mBODE scores, with 55 patients 
(37%) and 42 patients (28%) scoring 3 and 4, respectively. 
The median of the mDOSE score was 2, with the distribution 
of scores tending to skew toward the lower scores. There 
were significant relationships between the three   indices 
(mBODE vs ADO, correlation coefficients [rs] = 0.60, 
P , 0.0001; ADO vs mDOSE, rs = 0.55, P , 0.0001; and 
mDOSE vs mBODE, rs = 0.64, P , 0.0001).
Table  1  Multidimensional  staging  of  150  male  patients  with 
chronic obstructive pulmonary disease
Characteristics Mean ± SD Range
mBODE index (0–10) 4.3 ± 2.0 0–9
ADO index (0–10) 3.8 ± 1.2 1–7
mDOSE index (0–8) 2.2 ± 1.5 0–6
Note: On the mBODE, ADO, and mDOSE indices, higher scores indicate a more 
severe status.
Abbreviations: ADO, age, dyspnea, and airflow obstruction; mBODE, modified 
body  mass  index,  airflow  obstruction,  dyspnea,  and  exercise  capacity;  mDOSE, 
modified dyspnea, airflow obstruction, smoking status, and exacerbation frequency.
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Figure 1 Frequency distributions of the (A) mBODE score, (B) ADO score, and 
(C) mDOSE score in patients with chronic obstructive pulmonary disease. In each, 
a higher score indicates a more severe status.
Abbreviations: ADO, age, dyspnea, and airflow obstruction; mBODE, modified 
body  mass  index,  airflow  obstruction,  dyspnea,  and  exercise  capacity;  mDOSE, 
modified dyspnea, airflow obstruction, smoking status, and exacerbation frequency.
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Of the 150 patients enrolled, six were unavailable for 
follow-up and 31 patients died.9 Causes of death were as 
follows: 20 due to COPD or COPD-related diseases, four 
due to malignant disorders (two lung cancer cases), one due 
to myocardial infarction and hepatic failure, respectively, 
and five due to unknown reasons.
Univariate Cox proportional hazards analyses were 
performed to investigate the relationship between clinical 
indices and mortality (Table 2 and elsewhere9). Age, BMI, 
FEV1, peak   Vo2, MRC, and the SGRQ total score were all 
significantly related to mortality. All the mBODE, ADO, 
and mDOSE indices were strongly related to mortality 
(RR = 1.618, P , 0.0001; RR = 2.342, P , 0.0001; and 
RR = 1.521, P = 0.0002, respectively).
To investigate the abilities of the aforementioned three 
multidimensional staging methods to predict mortality as 
compared with airflow limitation, exercise capacity, dyspnea, 
and health status, multivariate Cox proportional hazards 
analyses were performed (Table 3). Model 1 includes three 
analyses investigating the relationships between each index 
and FEV1 with mortality. The mBODE and ADO indices 
were more significantly related to mortality than FEV1, but 
mDOSE index was not. Model 3 includes three analyses 
investigating the relationships between each index and MRC 
with mortality. The result was the same with Model 1. These 
results indicate that predictive properties of mBODE and 
ADO indices might be stronger than those of FEV1 and MRC 
as well as mDOSE index. In contrast, Model 2 includes three 
analyses investigating the relationships between each index 
and peak   Vo2 with mortality. Peak  Vo2 was more significantly 
related to mortality than all three indices (P , 0.0001), indi-
cating that the predictive property of exercise capacity might 
be stronger than different multidimensional staging. Model 
4 includes three analyses investigating the relationships 
between each index and SGRQ with mortality. In contrast 
with Model 2, all three indices were more significantly related 
to mortality than the SGRQ total score.
To investigate which of the mBODE, ADO, and mDOSE 
indices was the most significantly correlated with   mortality, 
stepwise multivariate Cox proportional hazards analysis was 
performed (Table 4). Both the mBODE and ADO indices were 
significantly related to mortality (RR = 1.351, P = 0.027; and 
RR = 1.653, P = 0.031) but not the mDOSE index (P = 0.87).
Discussion
We evaluated the predictive and discriminative properties of 
different multidimensional staging systems in patients with 
COPD. Among the mBODE, ADO, and mDOSE indices, 
the mBODE index seemed to have the best discriminative 
property. We found that all three indices were significantly 
predictive of mortality, although the predictive ability of the 
mDOSE tended to be inferior to the other two. In contrast, 
values for the peak  Vo2 on progressive cycle ergometry were 
more significantly correlated with mortality than any of the 
three multidimensional staging systems.
We previously examined predictors of mortality in 
patients with COPD and reported that exercise capacity, 
dyspnea, and health status were significantly related to mor-
tality independently of airflow limitation.9,20,21 These results 
suggested the need to incorporate these systemic elements in 
addition to FEV1 in evaluating patients with COPD. Among 
the three indices, the mBODE and ADO indices were more 
strongly predictive of mortality than FEV1, MRC, or SGRQ. 
Thus, these multidimensional staging systems seem to be 
more useful in prognostic assessments than airflow limitation, 
dyspnea, or health status alone in patients with COPD. After 
evaluating their properties well in different study situations, 
they will be used in clinical settings.
The relationships between the mBODE, ADO, and 
mDOSE indices were moderate, indicating that they do not 
necessarily evaluate the same aspects of COPD, although 
some components are common to all three indices. In fact, 
the stepwise multivariate Cox proportional hazards analysis 
showed that both the mBODE and ADO indices were inde-
pendently related to mortality in patients with COPD. Thus, 
using more than one index might have some complementarily 
or additive advantage in prognostic assessment.
There were differences in the discriminative proper-
ties among the mBODE, ADO, and mDOSE indices. The 
mBODE score was more widely and normally distributed 
than the scores of the other indices examined, indicating 
its superior discriminative property. In our single popula-
tion sample, the age component of the ADO index might 
have varied less widely than the original report of the ADO 
index,7 as shown here that about 65% of our patients scored 
3 or 4. Regarding the mDOSE index, firstly, its range from 
0 to 8 is narrower than the BODE and ADO indices ranging 
Table 2 Univariate Cox proportional hazards analyses in patients 
with chronic obstructive pulmonary disease
Relative risk 95% confidence interval P-value
mBODE index 1.618 1.301–2.013 ,0.0001
ADO index 2.342 1.662–3.300 ,0.0001
mDOSE index 1.521 1.223–1.890 0.0002
Abbreviations: ADO, age, dyspnea, and airflow obstruction; mBODE, modified 
body  mass  index,  airflow  obstruction,  dyspnea,  and  exercise  capacity;  mDOSE, 
modified dyspnea, airflow obstruction, smoking status, and exacerbation frequency.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
524
Oga et alInternational Journal of COPD 2011:6
from 0 to 10. Secondly, in the present study, the median score 
on the mDOSE index was low at 2, and its distribution was 
skewed toward lower scores, which were consistent with the 
original report.8 Thus, although the ADO and DOSE indices 
are simple and easy assessments for use in primary care set-
tings, as they do not include an exercise capacity component, 
their discriminative properties may be limited.
In the present study, peak  VO2 was more strongly related 
to mortality than the mBODE, ADO, and mDOSE indices, 
indicating that peak   VO2 is an important factor in COPD in 
relation to mortality. In addition to studies examining pre-
dictors of mortality in COPD,9 peak   VO2 is reported to be a 
useful prognostic factor in other disorders22,23 such as inter-
stitial lung diseases,24 primary pulmonary hypertension,25 
cyctic fibrosis,26 or chronic heart failure.27 Cardiopulmonary 
exercise testing has some utility in diagnosis and functional 
evaluation, and prognostic stratification is considered to be 
a major indication for cardiopulmonary exercise testing in 
patients with pulmonary or cardiac disorders.23
In the present study, we compared different multidimen-
sional staging systems from the viewpoint of the relationship 
of their scores with mortality. Although these or similar 
indices are sometimes referred to as disease severity indices, 
strictly speaking, disease severity in COPD has not been 
defined. When disease severity is considered according to 
the closeness of death, assessing results of these systems 
would be appropriate in predicting mortality. However, there 
are other ideas about defining disease severity, such as its 
relationship with health status or exacerbations. It seems that 
multidimensional staging is superior to the current means of 
disease staging based on the level of FEV1.28,29 A standardized 
definition of disease severity is needed to eliminate confusion 
and to officially establish a novel disease severity staging 
system not based solely on FEV1 in future.
As a limitation, although several multidimensional 
staging systems in addition to the BODE, ADO, and DOSE 
indices have been developed in recent years,30,31 we did not 
assess them in the present study.
Conclusion
We demonstrated that the multidimensional staging systems 
of the mBODE, ADO, and mDOSE indices were significant 
predictors of mortality in patients with COPD. The mBODE 
Table 3 Multivariate Cox proportional hazards analyses in patients with chronic obstructive pulmonary disease
Relative risk (95% confidence interval)
Model 1 (airflow limitation and multidimensional staging)
FEV1,%pred 0.972 (0.935–1.012) 0.967 (0.936–0.998)a 0.950 (0.920–0.980)b
mBODE index 1.379 (1.015–1.874)a NA NA
ADO index NA 1.913 (1.248–2.932)b NA
mDOSE index NA NA 1.199 (0.916–1.569)
Model 2 (exercise capacity and multidimensional staging)
Peak   Vo2, mL/min 0.995 (0.993–0.997)c 0.995 (0.993–0.997)c 0.994 (0.992–0.996)c
mBODE index 1.113 (0.852–1.455) NA NA
ADO index NA 1.328 (0.889–1.983) NA
mDOSE index NA NA 1.119 (0.854–1.467)
Model 3 (dyspnea and multidimensional staging)
MRC scale 1.163 (0.684–1.977) 1.248 (0.735–2.118) 1.697 (1.029–2.798)a
mBODE index 1.556 (1.203–2.012)c NA NA
ADO index NA 2.082 (1.334–3.249)b NA
mDOSE index NA NA 1.263 (0.955–1.670)
Model 4 (health status and multidimensional staging)
SGRQ total 1.014 (0.990–1.039) 1.019 (0.997–1.042) 1.014 (0.987–1.041)
mBODE index 1.545 (1.225–1.947)b NA NA
ADO index NA 2.169 (1.511–3.115)b NA
mDOSE index NA NA 1.384 (1.037–1.845)a
Notes: aP , 0.05, bP , 0.01, cP , 0.001.
Abbreviations: ADO, age, dyspnea, and airflow obstruction; FEV1, forced expiratory volume in 1 second; mBODE, modified body mass index, airflow obstruction, dyspnea, 
and exercise capacity; mDOSE, modified dyspnea, airflow obstruction, smoking status, and exacerbation frequency; MRC, Medical Research Council; NA, not applicable; 
SGRQ, St. George’s Respiratory Questionnaire; Vo2, peak oxygen uptake.
Table 4 Stepwise multivariate Cox proportional hazards analysis 
in patients with chronic obstructive pulmonary disease
Relative risk 95% confidence interval P-value
mBODE index 1.351 1.035–1.765 0.027
ADO index 1.653 1.047–2.610 0.031
mDOSE index 0.87
Abbreviations: ADO, age, dyspnea, and airflow obstruction; mBODE, modified 
body  mass  index,  airflow  obstruction,  dyspnea,  and  exercise  capacity;  mDOSE, 
modified dyspnea, airflow obstruction, smoking status, and exacerbation frequency.
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was superior to other indices for its discriminative property. 
An understanding of the properties or characteristics of the 
indices is important when using them in clinical practice, 
and, at the same time, a definition of disease severity needs 
to be established in order to propose the indices assessed in 
this report as a new disease severity index.
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